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Aspirin modestly influences cardiovascular events in patients
with type 2 diabetes mellitus (T2DM), but the reason is unclear.
The aim of the study was to determine whether in T2DM patients
aspirin enhances platelet isoprostanes, which are eicosanoids
with proaggregating properties derived from arachidonic acid
oxidation by platelet NOX2, the catalytic subunit of reduced NAD
phosphate oxidase. A cross-sectional study was performed com-
paring T2DM patients, treated (n = 50) or not treated (n = 50)
with 100 mg/day aspirin, with 100 nondiabetic patients, matched
for age, sex, atherosclerosis risk factors, and aspirin treatment.
A short-term (7 days) treatment with 100 mg/day aspirin also was
performed in 36 aspirin-free diabetic and nondiabetic patients.
Higher platelet recruitment, platelet isoprostane, and NOX2 acti-
vation was found in diabetic versus nondiabetic patients and in
aspirin-treated diabetic patients versus nontreated patients (P ,
0.001). Platelet thromboxane (Tx) A2 (P , 0.001) was inhibited in
all aspirin-treated patients. In the interventional study, aspirin sim-
ilarly inhibited platelet TxA2 in diabetic and nondiabetic patients
(P , 0.001). Platelet recruitment, isoprostane levels, and NOX2
activation showed a parallel increase in diabetic patients (P ,
0.001) and no changes in nondiabetic patients. These findings
suggest that in aspirin-treated diabetic patients, oxidative stress–
mediated platelet isoprostane overproduction is associated with
enhanced platelet recruitment, an effect that mitigates aspirin-
mediated TxA2 inhibition. Diabetes 61:1626–1632, 2012
A ccelerated atherosclerosis is a typical feature oftype 2 diabetes mellitus (T2DM). Thus, patientswith T2DM have a two- to fourfold increasedrisk of cardiovascular diseases (coronary artery
disease) and a two- to sixfold increased risk of stroke (1–3).
Platelets play a major role in the etiology of athero-
sclerotic disease, as shown by the significant decrease of
cardiovascular events in patients treated with aspirin, an
inhibitor of cyclooxygenase (COX1) that prevents platelet
thromboxane (Tx) A2 formation (4,5). Platelet TxA2 over-
production, combined with a significant decrease after aspirin
administration, has been demonstrated in diabetic patients
(6). Despite this, interventional trials with aspirin in di-
abetic patients failed to show a beneficial effect in pri-
mary prevention; reasons for this lack of response still
are uncertain (7).
Isoprostanes are a family of eicosanoids derived from
arachidonic acid interaction with reactive oxidant species
(ROS). Thus, ROS generated by NOX2, the catalytic subunit
of reduced NAD phosphate (NADPH) oxidase, play a crucial
role in platelet isoprostane formation (8). In contrast to TxA2,
isoprostanes are chemically stable compounds that serve
to propagate platelet activation, amplifying platelet re-
sponse to common agonists via glycoprotein (Gp)IIb/IIIa
activation (9). Accordingly, patients with hereditary de-
ficiency of NOX2 showed impaired isoprostane formation
and GpIIb/IIIa activation, as well as a subnormal propagation
of platelet thrombus (9).
It previously has been demonstrated that COX1 in-
hibition determines a shift in arachidonic acid metabolism
toward other pathways, such as the lipooxygenase system
(10). We speculated that COX1 inhibition also could be
associated with an increased conversion of arachidonic
acid to isoprostanes in platelets. The increase of platelet
isoprostanes would counterbalance the inhibition of TxA2,
therefore hampering the antiplatelet effect of aspirin. To
explore this hypothesis, we performed a cross-sectional
study comparing the behavior of platelet isoprostanes and
TxA2 and their interplay with platelet NOX2 in diabetic and
nondiabetic patients treated or not with aspirin. Platelet
activation tests, including arachidonic acid–induced platelet
aggregation, which is dependent upon TxA2 formation (11),
and platelet recruitment, which is dependent upon ROS
and isoprostane formation (9), were determined. Analysis
of these variables was repeated in a prospective, short-term
study of diabetic and nondiabetic patients treated for 7 days
with low-dose aspirin.
RESEARCH DESIGN AND METHODS
Study design
Cross-sectional study. The study was performed in consecutive T2DM
patients attending our metabolic outpatient clinic who were taking (n = 50) or
not taking (n = 50) low-dose (100 mg/day) aspirin. T2DM was diagnosed ac-
cording to the American Diabetes Association definition (12). As a control
group, we selected nondiabetic outpatients taking (n = 50) or not taking (n = 50)
low-dose aspirin who were matched to the diabetic group in terms of age, sex,
and history of vascular disease.
Low-dose aspirin treatment was defined as a self-reported daily intake of
100 mg acetylsalicylic acid at least in the previous month. Exclusion criteria
were 1) recent history (,3 months) of acute vascular events, 2) clinical di-
agnosis of type 1 diabetes (diagnosis of diabetes and insulin use before the age
of 35 years), 3) serum creatinine level .2.5 mg/dL, 4) active infection or ma-
lignancy, 5) cardiac arrhythmia or congestive heart failure, and 5) use of non-
steroidal anti-inflammatory drugs, vitamin supplements, or other antiplatelet
drugs, such as clopidogrel, in the previous 30 days. All participants provided
written informed consent. The local ethical committee approved the study pro-
tocol (approval no. Prot. 403/09-Rif. 1621/07.05.09). Diabetic patients received
different antidiabetes treatments: metformin (n = 57), subcutaneous insulin
(n = 25), sulfonylureas (n = 14), glinides (n = 6), glitazones (n = 3), and
dipeptidyl peptidase-4 inhibitor (n = 16).
Interventional study. We tested the effect of short-term treatment with 100
mg/day aspirin in diabetic (n = 18) and nondiabetic (n = 18) patients, not
currently under aspirin treatment and with no clinical history of vascular
diseases, who were matched for sex, age, and atherosclerotic risk factors.
Aspirin was given after dinner between 8:00 and 8:30 P.M., and adherence was
assessed by the pill-count method. Blood samples were collected before
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aspirin ingestion and after 3 and 7 days of treatment. The study was registered
in August 2010 at clinicaltrials.gov (clinical trial reg. no. NCT01250340).
Laboratory analyses. All materials were from Sigma-Aldrich, unless other-
wise specified. Blood analyses were performed in a blinded manner. All blood
samples were taken after a 12-h fast. Between 8:00 and 9:00 A.M., subjects
underwent routine biochemical evaluations, including fasting total cholesterol
and glucose.
Serum and platelet-poor plasma sampling. After overnight fasting (12 h)
and supine rest for at least 10 min, blood samples were taken into tubes
containing either 3.8% sodium citrate (ratio 9:1) or anticoagulant-free tubes and
centrifuged at 300g for 10 min to obtain supernatant (plasma or serum), which
was stored at 280°C until use.
Platelet-rich plasma preparation. To obtain platelet-rich plasma (PRP),
samples were centrifuged for 15 min at 180g. To avoid leukocyte contamina-
tion, only the top 75% of the PRP was collected; leukocyte contamination was
verified as reported below.
Washed-platelet procedure. Platelet pellets were obtained by double cen-
trifugation (2 3 5 min, 300g) of PRP after the addition of acid/citrate/dextrose
(1:7 vol/vol) to avoid cell activation during processing. Samples were sus-
pended in HEPES buffer in the presence of 0.1% albumin, pH 7.35 (2 3 105
platelets/mL, unless otherwise noted).
Platelet sizing. To assess if there were differences between T2DM patients
and control subjects in platelet size and function, we stratified in two portions
(50% upper phase, 50% lower phase) the top 75% of the PRP. After the washing
procedure of the two portions, we analyzed TxA2 and 8-iso-PGF2a-III
production.
Cytometric analysis of platelets and leukocytes. Leukocyte content in the
top 75% of the PRP was analyzed using the specific fluorescein isothiocyanate–
labeled monoclonal antibody (Mab) anti-CD4 (BD International). Platelets were
analyzed using the specific phycoethrin-labeled monoclonal antibodies anti-
CD61 (Mab) (BD International).
All assays included samples to which an irrelevant isotype-matched anti-
body (fluorescein isothiocyanate–labeled IgG1 or phycoethrin-labeled IgG1)
was added. Fluorescence intensity was analyzed on an Epics XL-MCL Cytom-
eter (Coulter Electronics, Hialeah, FL) equipped with an argon laser at 488
nmol/L. For every histogram, 5 3 104 platelets were counted to evaluate the
percentage of positive platelets. Antibody reactivity is reported as mean fluo-
rescence intensity and percentage (%) of positivity.
Platelet NOX2, TxA2, 8-iso-PGF2a-III, and ROS. Platelet suspension was
activated with arachidonic acid (1 mmol/L), and the supernatant was treated
with butylhydroxytoluene and stored at 280°C. In some experiments, samples
were treated with or without NOX2-blocking peptide (gp91phox ds-tat–blocking
peptide, 50 mmol/L) (10 min 37°C) before activation.
Extracellular levels of soluble NOX2-derived peptide (sNOX2-dp), a marker
of NADPH oxidase activation, were detected by enzyme-linked immunosorbent
assay, as previously described by Pignatelli et al. (13). The peptide was rec-
ognized by the specific monoclonal antibody against the amino acidic sequence
(224–268) of the extra membrane portion of NOX2, which was released in the
medium upon platelet activation. Values were expressed as picograms per
milliliter; intra-assay and interassay coefficients of variation were 5.2 and 6%,
respectively.
Platelet TxB2 was measured by enzyme-linked immunosorbent assay
(Amersham Pharmacia, Biotech, Little Chalfont, U.K.) and expressed as
picomoles per liter. TxB2 levels in all experiments were expressed as defined
in the following formula: (TxA2 in stimulated samples) 2 (TxA2 in unstimu-
lated samples). Intra- and interassay coefficients of variation were 4.0 and
3.6%, respectively.
The platelet isoprostane 8-iso-PGF2a-III was measured by the enzyme im-
munosorbent assay method, as previously described (9), and expressed as
picomoles per liter. In a subgroup of patients (n = 20), platelet isoprostane
levels also were measured by gas mass chromatography (7890A GC-MS; Agi-
lent Technologies) to validate the method (14). Intra- and interassay coef-
ficients of variation were 5.8 and 5.0%, respectively.
To evaluate ROS formation, cell suspension was incubated with 29,79-
dichlorofluorescin diacetate (5 mmol/L) for 15 min at 37°C. ROS production
was evaluated by flow cytometric analysis and expressed as stimulation index
(mean level of fluorescence in stimulated cells/mean level of fluorescence in
unstimulated cells; stimulation index), as previously described (11). Intra- and
interassay coefficients of variation were 4%.
Platelet aggregation. Platelet aggregation was induced by arachidonic acid
(1.0 mmol/L) and measured as light transmission (LT%) difference between
PRP and platelet-poor plasma, as previously described (11).
Platelet recruitment. Platelet recruitment was performed with a method
modified from that described by Krötz et al. (15). Collagen (2 mg/mL)-induced
platelet aggregation was measured for 10 min, then an equal portion of un-
treated platelets was added to each tube, causing a reduction in light trans-
mission. This method consists of two phases, the first one depending on the
agonist (collagen) and the second one depending on the release of mole-
cules discharged by activated platelets (ADP, isoprostanes, etc.). Thus, the
second phase (recruitment) is independent from the agonist (collagen) ini-
tially added to the first phase of aggregation because collagen is fully taken
up by platelets during the first phase (16). Aggregation of the newly added
platelet portion in the presence of an existing aggregate was then measured
for 5 min and expressed as a percentage (REC%) of the aggregation that
had been initially reached, according to Pignatelli et al. (9). In some experi-
ments, PRP samples were incubated (30 min at 37°C) with or without TxA2/
isoprostane receptor inhibitor (SQ29548, 0.1 mmol/L) or control before collagen
stimulation.
Flow cytometry analysis of GpIIb/IIIa activation (pituitary adenylate
cyclase-activating peptide receptor 1 [PAC1] binding). Platelet GpIIb/IIIa
activation was measured by PAC1 binding on platelet membranes, as previously
reported, and expressed as mean fluorescence intensity (17). GpIIb/IIIa activation
was analyzed after platelet suspension incubation with scalar doses of 8-iso-
PGF2a (25–450 pmol/L) with or without the TxA2/isoprostane receptor antagonist
SQ29548 (0.1 mmol/L), ADP (0.01–10 mmol/L) with or without 8-iso-PGF2a (300
pmol/L), and thrombin receptor agonist peptide (TRAP) (0.01–10 mmol/L).
Statistical analysis. The minimum sample size was computed with respect to
a two-tailed Student t test for independent groups, considering 1) relevant
difference in isoprostane levels to be detected between groups |d| $90 pmol/L,
2) SDs homogeneous between the groups (SD = 80 pmol/L), and 3) type I error
probability a = 0.05 and power 1-b = 0.90. This resulted in n = 17 per group.
Categorical variables were reported as counts (percentage) and continuous
variables were expressed as means 6 SD, unless otherwise indicated. Differ-
ences between percentages were assessed by the x2 test or Fisher exact test.
Student unpaired t test and Pearson product moment correlation analysis were
used for normally distributed continuous variables. Appropriate nonparametric
tests (Mann-Whitney U test and Spearman rank correlation test [Rs]) were used
for all the other variables. Multiple linear regression analysis was performed to
further quantify the relationship between the variables studied.
Interventional study data were analyzed performing a MANOVA with one
between-subject factor (group: diabetic vs. nondiabetic patients) and one
within-subject factor (time: baseline, 3 days, and 7 days after initiation of
treatment). As covariates, we considered the possible random differences in
age, sex, BMI, smoking habits, and hypertension between the two groups.
Pairwise comparisons were performed using Bonferroni correction. Probability
values ,0.05 were regarded as statistically significant. All calculations were
made with Statistica 7 software for Windows (StatSoft, Tulsa, OK).
RESULTS
Cross-sectional study. Diabetic and nondiabetic patients
had a similar distribution of risk factors, with the exception
of BMI, which was higher in diabetic patients (Table 1).
Statin therapy was more common in diabetic patients
(P = 0.015). Diabetic and nondiabetic patients had similar
platelet TxB2 values (Fig. 1A) and platelet aggregation
percentages (95 6 3 vs. 96 6 2 LT%, respectively; P =
0.864). Diabetic patients had significantly higher platelet
isoprostanes, platelet recruitment, and sNOX2-dp compared
with nondiabetic patients (Fig. 1B–D). In diabetic patients,
HbA1c significantly correlated with sNOX2-dp (r = 0.40,
P, 0.0001) and platelet isoprostanes (r = 0.39, P, 0.0001).
Diabetic patients treated or not with aspirin had similar
clinical characteristics (Table 1) and received equally dis-
tributed different antidiabetes treatment (data not shown).
Platelet TxB2 was significantly lower in aspirin-treated di-
abetic patients; conversely, aspirin-treated diabetic patients
had higher platelet isoprostanes, platelet recruitment, and
NOX2 activation (Fig. 1).
In nondiabetic patients, aspirin treatment significantly
lowered platelet TxB2 compared with aspirin-untreated
patients. However, no significant differences were found in
platelet isoprostanes, platelet recruitment, and sNOX2-dp
levels between nondiabetic patients treated or not with as-
pirin (Fig. 1). Similar results were observed comparing
control subjects with impaired fasting glucose (n = 22) taking
(n = 10) or not taking (n = 12) aspirin (data not shown).
Platelet aggregation was completely suppressed in aspirin-
treated diabetic and nondiabetic patients (not shown).
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Correlation analysis. In the overall population, platelet
isoprostanes significantly correlated with platelet re-
cruitment (r = 0.43, P , 0.001) and sNOX2-dp (r = 0.49,
P , 0.001). To further define the predictors of the platelet
isoprostane level, multiple regression analysis including
clinical and laboratory characteristics, presence of diabe-
tes, and concomitant use of aspirin and statins was per-
formed. Stepwise linear regression yielded a model in
which only T2DM (b = 0.276, P , 0.001), aspirin treatment
(b = 0.158, P = 0.009), and sNOX2-dp (b = 0.229, P, 0.001)
predicted platelet isoprostane levels, independently from
the other included variables.
Interventional study. Clinical and anthropometric char-
acteristics of interventional study participants are reported
in Table 2.
At baseline, platelets from diabetic and nondiabetic
patients showed similar platelet TxB2 values (Fig. 2) and
platelet aggregation percentages (94 6 2.2 vs. 97 6 3 LT
%; P = 0.640). Conversely, platelet recruitment, platelet
isoprostanes, platelet ROS, and sNOX2-dp were signifi-
cantly higher in diabetic compared with nondiabetic
patients. Platelet TxB2 formation (Fig. 2A) and platelet
aggregation (not shown) were significantly inhibited af-
ter aspirin intake in both groups. Platelet isoprostanes,
sNOX2-dp, platelet ROS, and platelet recruitment in-
creased after aspirin intake only in diabetic patients
(Fig. 2).
MANOVA analysis showed a significant influence of as-
pirin treatment in diabetic patients on platelet iso-
prostanes (F = 11.9, P , 0.001), platelet ROS production
(F = 171.6, P, 0.001), sNOX2-dp (F = 32.5, P, 0.001), and
platelet recruitment (F = 9.6, P , 0.001). No significant
interaction with covariates was found. Incubation of plate-
lets from aspirin-treated diabetic patients with the NOX2-
blocking peptide was associated with a significant inhibition
of ROS (23.3 S.I. at 3 days, P = 0.006, and27.9 S.I. at 7 days,
P = 0.003, respectively) and platelet isoprostane (2134
pmol/L at 3 days, P , 0.001, and 2137 pmol/L at 7 days,
P = 0.005) production. Conversely, in aspirin-treated non-
diabetic patients, NOX2-blocking peptide had a less
significant effect on platelet ROS (20.8 stimulation index
at 3 days, P = 0.023, and 20.9 S.I. at 7 days, P = 0.021) and
isoprostane (26 pmol/L at 3 days, P = 0.048, and 27 pmol/L
at 7 days, P = 0.043) production.
The Tx/isoprostane inhibitor SQ29548 significantly in-
hibited recruitment of platelets from aspirin-treated dia-
betic patients but not from aspirin-treated nondiabetic
patients (Fig. 2E and F).
In vitro study
Effect of 8-iso-PGF2a on platelet activation. TRAP
(0.01–10 mmol/L) dose-dependently increased GpIIb/IIIa
activation (Fig. 3). Compared with TRAP, GpIIb/IIIa acti-
vation by 8-iso-PGF2a (25–350 pmol/L) was weaker and
significantly inhibited by platelet coincubation with SQ29548.
GpIIb/IIIa activation by ADP also was dose dependent; it
almost was undetectable with doses ,0.1 mmol/L and be-
came detectable with values .1 mmol/L. The incubation of
8-iso-PGF2a (300 pmol/L) with lower ADP doses (0.01–0.1
mmol/L) amplified GpIIb/IIIa activation with values similar
to those achieved with higher ADP doses.
Influence of platelet size in eicosanoids formation.
The top 75% of the PRP of diabetic and control subjects
was stratified in two portions (50% upper and 50% lower
phases). Arachidonic acid-induced platelet TxB2 and iso-
prostanes were measured in both phases. Platelets from
diabetic patients were greater in the upper 50% (Fig. 4ATA
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and B), whereas no difference was detected in the lower
phase. The increase in eicosanoids formation between di-
abetic patients and control subjects persisted in the two
phases, suggesting that platelet size was not a determinant
in the above-reported differences (Fig. 4C and D).
Leukocyte contamination. To ensure the quality of
platelet preparation, samples also were tested for leuko-
cyte contamination. The contamination found was ,1% in
all samples (an exemplificative image of flow cytometric
analysis is shown in Fig. 4A and B)
FIG. 1. TxB2 (A) and isoprostane formation (B), platelet recruitment (REC%) (C), and sNOX2-dp (D) from arachidonic acid–activated platelets in
nondiabetic and diabetic patients taking (ASA+) or not (ASA2) 100 mg acetylsalicylic acid daily in the previous month. *P < 0.001.
TABLE 2
Clinical and anthropometric characteristics of interventional study participants
Diabetic patients Nondiabetic patients P
n 18 18
Age (years) 62.3 6 9.4 61.6 6 10.1 0.886
Male (%) 61 56 0.735
BMI (kg/m2) 27.3 6 4.3 27.0 6 2.8 0.789
Arterial hypertension (%) 77 72 0.700
Previous coronary artery disease (%) 0 0 1.000
Previous stroke (%) 0 0 1.000
Total cholesterol (mg/dL) 188.1 6 36.4 186.8 6 37.2 0.385
HDL cholesterol (mg/dL) 51.4 6 16.6 50.8 6 15.8 0.472
Triglycerides (mg/dL) 144.5 6 63.2 134.2 6 51.8 0.239
Blood glucose (mg/dL) 140.2 6 35.4 91.5 6 9.8 ,0.001
HbA1c (%) 7.1 6 1.4 5.5 6 0.4 ,0.001
Statin therapy (%) 11 6 0.546
ACE/angiotensin receptor blockers (%) 67 61 0.729
Antidiabetes drugs (%) 89 0 ,0.001
Data are means 6 SD, unless otherwise indicated.
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DISCUSSION
This study provides evidence that, in diabetic patients
treated with low-dose aspirin, platelets overproduce
isoprostanes, an effect that is dependent upon enhanced
formation of ROS generated by NOX2 activation. Platelet
ROS plays a central role in the propagation of platelet
aggregation by inactivating platelet nitric oxide, releasing
ADP, and producing isoprostanes (9,18). Previous studies
FIG. 2. TxB2 (A) and isoprostane (B) formation, sNOX2-dp release (C), and ROS production (D) from arachidonic acid-activated platelets in
nondiabetic and diabetic patients at baseline and after 3 and 7 days of aspirin (100 mg) treatment. E and F: Platelet recruitment (REC%) in diabetic
and nondiabetic patients at baseline and after 3 and 7 days of low-dose aspirin treatment in the presence or not of SQ29548 (0.1 mmol/L). *P< 0.001.
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showed that diabetic patients have a systemic isoprostane
overproduction (19,20), but the role of platelets has never
been examined. The cross-sectional study showed enhanced
platelet isoprostane formation and platelet recruitment along
with NOX2 activation in diabetic versus nondiabetic patients
without aspirin treatment.
Comparing diabetic and nondiabetic patients treated or
not with aspirin, a great behavioral difference between the
two platelet eicosanoids was detected. Thus, in nondiabetic
patients, aspirin inhibited platelet TxB2 without affecting
platelet isoprostanes. Conversely, diabetic patients on as-
pirin treatment showed platelet TxB2 inhibition but a higher
isoprostanes production compared with aspirin-untreated
diabetic patients. The increase in isoprostane levels was
associated with enhanced platelet NOX2 activation. This
reinforces the hypothesis that NOX2 is crucial for the ROS
overproduction observed in T2DM (21) and suggests a role
for NOX2 in platelet isoprostane overproduction in T2DM.
Furthermore, our data reinforce previous reports showing
that NOX2 upregulation occurs in diabetes not only in the
endothelial cells but also in platelets (22). Hyperglycemia is
likely to play a major role as also indicated by the direct
correlation between HbA1c and sNOX2-dp, but the underlying
mechanism still is controversial (23).
The different effect of aspirin on TxB2 and isoprostanes
likely accounts for the divergent behavior of platelet
function tests in aspirin-treated diabetic patients. Although
arachidonic acid–induced platelet aggregation was inhibi-
ted, platelet recruitment was enhanced. To further support
these findings, we measured platelet TxB2 and isoprostanes
in diabetic and nondiabetic patients before and after short-
term aspirin treatment. Although both groups disclosed
a similar platelet TxB2 inhibition, platelet isoprostanes
showed a different behavior. In nondiabetic patients,
platelet isoprostane formation was not influenced by as-
pirin, and in diabetic patients isoprostanes increased 3 and
7 days after aspirin treatment. This change in isoprostane
levels was coincidental with enhanced platelet ROS for-
mation and NOX2 activation, suggesting a cause-and-effect
relationship between NOX2-generated ROS and platelet
isoprostane overproduction. This hypothesis was supported
by ex vivo experiments where platelets were incubated with
a specific NOX2 inhibitor. The NOX2 inhibitor significantly
inhibited platelet ROS and isoprostanes in both diabetic and
nondiabetic patients with a reduction of the two variables
that was, however, much higher in T2DM patients.
A crucial issue of the study was to establish if platelet
isoprostane increase observed after aspirin treatment was
functionally relevant in diabetic patients (i.e., it was as-
sociated with platelet activation). We found no changes in
platelet recruitment in nondiabetic but an increase in di-
abetic patients. Of note, platelet incubation with the TxA2/
isoprostane receptor antagonist prevented platelet recruit-
ment increase in diabetic but not in nondiabetic patients. We
speculated that this different behavior could depend upon
the 8-iso-PGF2a concentration expressed by platelets from
the two groups. To evaluate this, we conducted in vitro
experiments to analyze the interplay between isoprostane
concentration and GpIIb/IIIa activation (9). A dose-response
curve with scalar concentration of 8-iso-PGF2a demon-
strated that GpIIb/IIIa was activated in a range of 250–350
pmol/L, which is close to the level of isoprostanes produced
by platelets from aspirin-treated diabetic patients (~300
pmol/L) but higher than that expressed by platelets from
aspirin-treated nondiabetic patients (~200 pmol/L). To-
gether, these data indicate that in diabetic patients aspirin
enhances the platelet production of isoprostanes up to
functionally relevant concentrations, so enhancing platelet
recruitment via GpIIb/IIIa activation.
The study has pathophysiologic and clinical implica-
tions. The upregulation of NOX2 in T2DM has important
functional consequences, as it is associated with enhanced
ROS and isoprostane production and ultimately with platelet
activation. This finding supports and extends previous data
indicating that platelet ROS formation are implicated in the
FIG. 3. GpIIb/IIIa activation in platelets treated with a scalar dose of
8-iso-PGF2a (25–450 pmol/L) treated or not with SQ29548 (0.1 mmol/L),
ADP (0.01–10 mmol/L) treated or not with 8-iso-PGF2a (300 pmol/L),
and TRAP (0.01–10 mmol/L) (values are mean of experiments performed
in five healthy subjects). *P < 0.001.
FIG. 4. Platelet sizing and leukocyte contamination in the top 75% of the
PRP in nondiabetic patients (A) and in diabetic patients (B). Evaluation
of TxB2 (C) and isoprostanes (D) production in the stratified two
portions of the top 75% of the PRP (50% upper phase, 50% bottom phase;
up and down, respectively). Values are means of experiments performed
in five nondiabetic patients and five diabetic patients. *P < 0.001.
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thrombus formation process (18) and provides further in-
sight into the association between T2DM and thrombosis.
The upregulation of NOX2-generated ROS is likely to
have a negative impact on the antiplatelet effect of aspirin
in diabetic patients. In T2DM, the inhibition of COX1 by
aspirin could favor a shift of arachidonic acid toward other
metabolic pathways with ensuing enhancement of ROS-
mediated nonenzymatic oxidation of arachidonic acid and
subsequent isoprostane overproduction. Accordingly, pre-
vious studies showed that arachidonic acid activates
NADPH oxidase via interaction with p47phox, a subunit of
NADPH oxidase (24,25).
Such effect represents a plausible explanation for the
lower efficacy of aspirin in preventing cardiovascular events
in diabetic patients, as the divergent effect on platelet TxA2
and isoprostanes has a different impact on platelet activa-
tion. The suppression of the early phase of platelet aggre-
gation by TxA2 may be counterbalanced by the increased
propagation of platelet aggregation elicited by isoprostane
overproduction. The inhibition of this last effect by in vitro
addition of TxA2/isoprostane receptor antagonist suggests
a potential benefit of drugs that antagonize TxA2/isoprostane
receptors in patients with T2DM. Prevention of isoprostane
overproduction via inhibition of NOX2-generated ROS is
another attractive option to be considered. Statins have
been reported to downregulate systemic isoprostanes with
a mechanism that may involve inhibition of NADPH oxi-
dase (13,26). Therefore, it could be interesting to examine
if statins improve the antiplatelet effect of aspirin via in-
hibition of platelet isoprostanes.
A limitation of the study is the lack of analysis of aspirin
compliance in the cross-sectional study. However, both
diabetic and control groups had similar values of platelet
TxB2, indicating that a scarce adherence to aspirin treatment,
if any, was well balanced between the two. Furthermore,
platelet function analysis was performed in vitro and ex vivo,
which may not reflect platelet activation in vivo. Pharmaco-
logic study with an inhibitor of isoprostane receptors could
be useful to explore our study hypothesis in vivo.
In conclusion, we provide evidence that, in T2DM patients,
low-dose aspirin enhances platelet isoprostanes as a con-
sequence of NOX2-generated ROS upregulation. This effect
mitigates the antiplatelet effect of aspirin and may account
for its lower clinical efficacy in T2DM compared with other
atherosclerotic settings.
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